Update from the Novartis CMT1A Development Team
As you know, the CMT Research Foundation is proud to have introduced DTx leadership to Charcot-Marie-Tooth disease in 2019. We funded their first work in CMT to demonstrate the FALCON platform’s potential to deliver a drug to the Schwann cells. And from there,...![Arthur Suckow, former Co-founder and Chief Executive Officer of DTx Pharma, Joins CMT Research Foundation Board of Directors](https://cmtrf.org/wp-content/uploads/2023/10/Cleary-Edritz-Susan-Artie-1080x675.jpg)